ArticleFrontiers in immunology2021

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.

Jack Arnold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.